Mer­ck ex­tends pact with NK cell spe­cial­ists at Arti­va; Re­gen­eron-al­lied biotech pen­cils in $15M IPO

More than a year in­to its dis­cov­ery pact with the NK cell spe­cial­ists at Arti­va, Mer­ck is ap­par­ent­ly hap­py with what it’s seen so far.

So hap­py, in fact, that it wants to try new things with the plat­form.

The phar­ma gi­ant has struck a sep­a­rate deal to test the com­bi­na­tions of tri-spe­cif­ic NK cell en­gager can­di­dates with AB-101 NK cells gen­er­at­ed from Arti­va’s off-the-shelf NK cell ther­a­py plat­form. Al­though Mer­ck did not spec­i­fy which can­di­dates it will be pair­ing with those NK cells, the name is rem­i­nis­cent of the TriN­KETs it li­censed from Drag­on­fly Ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER